Source:http://linkedlifedata.com/resource/pubmed/id/19211934
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
19
|
| pubmed:dateCreated |
2009-5-8
|
| pubmed:abstractText |
Haploidentical hematopoietic stem cell transplantation provides an option for patients with advanced hematologic malignancies lacking a compatible donor. In this prospective phase 1/2 trial, we evaluated the role of reduced-intensity conditioning (RIC) followed by early add-backs of CD8-depleted donor lymphocyte infusions (DLIs). The RIC regimen consisted of thiotepa, fludarabine, cyclophosphamide, and 2 Gy total body irradiation. Twenty-eight patients with advanced lymphoproliferative diseases (n = 24) or acute myeloid leukemia (n = 4) were enrolled. Ex vivo and in vivo T-cell depletion was carried out by CD34(+) cell selection and alemtuzumab treatment. The 2-year cumulative incidence of nonrelapse mortality was 26% and the 2-year overall survival (OS) was 44%, with a better outcome for patients with chemosensitive disease (OS, 75%). Overall, 54 CD8-depleted DLIs were administered to 23 patients (82%) at 3 different dose levels without loss of engraftment or acute toxicities. Overall, 6 of 23 patients (26%) developed grade II-IV graft-versus-host disease, mainly at dose level 2. In conclusion, our RIC regimen allowed a stable engraftment with a rather low nonrelapse mortality in poor-risk patients; OS is encouraging with some long-term remissions in lymphoid malignancies. CD8-depleted DLIs are feasible and promote the immune reconstitution.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
1528-0020
|
| pubmed:author |
pubmed-author:Carlo-StellaCarmeloC,
pubmed-author:CarnitiCristianaC,
pubmed-author:CorradiniPaoloP,
pubmed-author:Di TerlizziSimonaS,
pubmed-author:DoderoAnnaA,
pubmed-author:FarinaLuciaL,
pubmed-author:GandolaLorenzaL,
pubmed-author:LombardoClaudiaC,
pubmed-author:LongoniPaoloP,
pubmed-author:MilanesiMarcoM,
pubmed-author:RaganatoAnnaA,
pubmed-author:SpinaFrancescoF,
pubmed-author:VendraminAntonioA
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
7
|
| pubmed:volume |
113
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
4771-9
|
| pubmed:meshHeading |
pubmed-meshheading:19211934-Adolescent,
pubmed-meshheading:19211934-Adult,
pubmed-meshheading:19211934-Aged,
pubmed-meshheading:19211934-Antigens, CD8,
pubmed-meshheading:19211934-Feasibility Studies,
pubmed-meshheading:19211934-Graft vs Host Disease,
pubmed-meshheading:19211934-Hematologic Neoplasms,
pubmed-meshheading:19211934-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:19211934-Humans,
pubmed-meshheading:19211934-Immunoglobulin Heavy Chains,
pubmed-meshheading:19211934-Immunophenotyping,
pubmed-meshheading:19211934-Lymphocyte Depletion,
pubmed-meshheading:19211934-Middle Aged,
pubmed-meshheading:19211934-Neoplasm Recurrence, Local,
pubmed-meshheading:19211934-Prospective Studies,
pubmed-meshheading:19211934-Receptors, Antigen, T-Cell,
pubmed-meshheading:19211934-Survival Rate,
pubmed-meshheading:19211934-T-Lymphocytes,
pubmed-meshheading:19211934-Transplantation, Homologous,
pubmed-meshheading:19211934-Transplantation Conditioning,
pubmed-meshheading:19211934-Treatment Outcome,
pubmed-meshheading:19211934-Young Adult
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery.
|
| pubmed:affiliation |
Division of Hematology and Bone Marrow Transplantation, Istituto Nazionale dei Tumori, Milan, Italy.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|